Telstra tops $100 million in healthcare investments

Telstra (ASX: TLS) announced today that it has acquired a 50% stake in Fred IT Group, one of Australia’s top health care IT companies. Although Telstra’s official press release didn’t disclose any financial details of the transaction, the Australia Financial Review noted that market sources priced the deal at approximately $25 million.

This isn’t Telstra’s first foray into health care technology, and the company is quickly working to make a name for itself in the $120 billion per year health care market. Shane Solomon, Telstra’s head of health, said in a statement that he and his company “are excited by the opportunities this investment presents and we will work with the Fred IT Group to build on the great foundations they have established.”

Telstra previously acquired health care software company DCA eHealth Solutions, health record company IPhealth, and appointment booking company Health Engine. Fred IT’s focus rounds out Telstra’s expertise in electronic prescription exchanges via cloud computing.

Foolish takeaway

A telecom company headed into health care should be enough to set “diworsification” alarm bells off in any investor’s head. But don’t sell so soon. Technology is a pervasive tool, and Telstra seems to be harnessing its skills to complement its steady entry into the lucrative health care market. With around $100 million already invested in health care technology market, Telstra is slowly but surely building itself a formidable force.

Every Aussie investor knows Telstra, but recent developments like its new Health division have kept investors guessing: Should you buy, sell or hold Telstra shares in our brand-new report, written by a top Motley Fool analyst. It’s free, click here for your instant download!

More reading

Motley Fool contributor Justin Loiseau has no position in any stocks mentioned in this article. You can follow him on Twitter @TMFJLo.

Top 3 ASX Blue Chips To Buy For 2019

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked…

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of The Motley Fool’s Top 3 Blue Chip Stocks for 2019.

Each one pays a fully franked dividend. The names of these Top 3 ASX Blue Chips are included in a specially prepared FREE report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

See the 3 blue chip stocks

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.